Application of myristyl ether in preparation of medicine for treating or preventing cardiovascular diseases

By pre-administration of H9c2 cardiomyocytes and MIRI rat hearts with myristyl ether, the problem of myocardial ischemia and reperfusion injury was solved, significantly reducing myocardial infarction area and cell damage, improving myocardial function, and providing more effective cardiovascular Disease treatment plan.

CN118924735AActive Publication Date: 2024-11-12INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411023825.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

Myocardial ischemia and reperfusion injury (MI/RI) exists in the treatment of cardiovascular disease. The existing anti-inflammatory and antioxidant effects are limited by pharmacokinetics and other factors, making it difficult to effectively reduce the impact of MI/RI.

Method used

Myristyl ether is used as the only active ingredient to protect H9c2 cardiomyocytes and the heart of MIRI rats through pre-administration, reduce the area of ​​myocardial infarction, improve myocardial contraction function, reduce the levels of AST, CK, CKMB, LDH in the blood, and reduce myocardial muscles. Cell damage and death enhance intracellular SOD activity and reduce apoptosis.

Benefits of technology

Myristyl ether significantly reduces the area of ​​myocardial infarction, improves myocardial contraction function, reduces inflammation and apoptosis, improves the protective effect of cardiomyocytes, and provides a more effective treatment plan for cardiovascular disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924735A_ABST
    Figure CN118924735A_ABST
Patent Text Reader

Abstract

The invention provides application of myristyl ether in preparation of a medicine for treating or preventing cardiovascular diseases. The application finds that myristyl ether has multiple protection effects on myocardial ischemia reperfusion injury: the myocardial infarction area is reduced; the myocardial contraction function is improved; myocardial interstitial edema, myocardial cell morphological change and inflammatory cell infiltration are relieved; the levels of AST, CK, CKMB and LDH in blood are reduced; myocardial cell damage and death are reduced; the LDH leakage of myocardial cells is reduced, and the SOD activity in the cells is enhanced; the myocardial cell apoptosis is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of cardiovascular disease treatment. Specifically, the present application provides the use of myristicin in the preparation of drugs for treating or preventing cardiovascular diseases. Background Art

[0002] Cardiovascular disease has become one of the leading causes of death in the world. The clinical treatment of cardiovascular disease is mainly based on surgery and drug therapy, among which surgical treatment can achieve rapid recovery of ischemic myocardial blood supply. However, the sudden blood supply process will increase the blood volume of the collateral circulation, and revascularization will lead to the activation of myocardial ischemia-reperfusion injury (MI / RI), which accounts for 40% of the area of ​​myocardial infarction. Myocardial infarction is a key factor affecting the treatment effect of coronary heart disease, and its pathogenesis is complex. MI / RI can cause inflammatory response, damage the living tissue around the infarction, and destroy the mitochondrial membrane potential, leading to the formation of reactive oxygen species (ROS). There are many methods for the treatment of myocardial infarction / RI in clinical practice, including anti-inflammatory, antioxidant, ischemic preconditioning and drug preconditioning. The administration of vitamin C and vitamin E after coronary artery surgery can significantly reduce myocardial infarction by anti-oxidative stress. However, many anti-inflammatory and antioxidant drugs are limited by pharmacokinetics and other factors. Finding suitable drugs to reduce MIRI has become a key issue that needs to be solved in the clinical treatment of myocardial ischemia.

[0003] Myristicin (abbreviated as Myr), belonging to the family of allylbenzene compounds, is a natural active ingredient in many spices, medicinal plants and some food spices (such as nutmeg, basil, cinnamon, cloves, parsley, carrots and black pepper). It has multiple biological effects, including antibacterial, antioxidant, anti-inflammatory, antiproliferative and anticancer properties. In traditional medicine, myristicin has been used to treat cholera, stomach cramps, nausea, diarrhea and anxiety, and no other pharmacological effects have been found. Summary of the invention

[0004] The applicant found that pre-administration of myristic ether has an excellent cardioprotective effect: myristic ether has a significant protective effect on H9c2 cardiomyocytes injured by H / R and on the hearts of MIRI rats.

[0005] In one aspect, the present application provides the use of myristicin in the preparation of a drug for treating or preventing cardiovascular diseases.

[0006] Furthermore, the cardiovascular disease is myocardial ischemia-reperfusion injury.

[0007] Furthermore, the drug provides one or more of the following effects:

[0008] (1) Reduce myocardial infarction area;

[0009] (2) Improve myocardial contractile function;

[0010] (3) Reduce myocardial interstitial edema, myocardial cell morphological changes, and inflammatory cell infiltration;

[0011] (4) Reduce the levels of AST, CK, CKMB, and LDH in the blood;

[0012] (5) Reduce cardiomyocyte damage and death;

[0013] (6) Reduce LDH leakage and enhance intracellular SOD activity;

[0014] (7) Reduce myocardial cell apoptosis.

[0015] Furthermore, myristicin is the only active ingredient in the drug.

[0016] Furthermore, the medicine also contains pharmaceutically acceptable excipients.

[0017] Furthermore, the pharmaceutically acceptable excipients are selected from one or more of fillers, binders, lubricants, disintegrants, coating agents, capsule shells, solvents, cosolvents, emulsifiers, pH regulators, osmotic pressure regulators, antioxidants, preservatives, flavoring agents, and colorants.

[0018] Furthermore, the drug is in the form of oral or parenteral administration.

[0019] Furthermore, the medicine is in the form of tablets, capsules, oral liquids, granules, pills, aqueous injections, or powder injections.

[0020] Furthermore, the medicine is in the form of an oral liquid.

[0021] Furthermore, the minimum dosage unit of the drug contains an amount of myristicin equivalent to 10 mg / kg rat.

[0022] Those skilled in the art can calculate the dosage for different subjects (eg, humans) according to algorithms known in the art (eg, skin surface area conversion, body weight conversion).

[0023] The minimum dosage unit of a pharmaceutical composition refers to one tablet, one capsule, one bag of granules or one injection, etc.

[0024] In another aspect, the present application provides a non-therapeutic method for protecting cardiomyocytes, comprising administering myristic acid ether to cardiomyocytes.

[0025] The non-therapeutic method can be used for non-therapeutic purposes such as scientific research and sample preservation, and is preferably performed in vitro.

[0026] Furthermore, the cardiomyocytes are H9c2 cardiomyocytes.

[0027] Furthermore, in the method, 12.5-50 μM myristicin is used to treat the cardiomyocytes.

[0028] Furthermore, the cardiomyocytes undergo a hypoxia / reoxygenation process.

[0029] The dosage form of the present invention can be produced by any method commonly used in pharmaceutical preparation technology, without particular limitation. For example, the oral liquid of the present invention can be extracted, purified, concentrated, packaged, sterilized, etc. using suitable methods known in the art. The oral liquid is subject to quality inspection, including appearance inspection (clarity inspection), device difference inspection, hygiene inspection, qualitative identification, determination of active ingredient content, determination of relative density, etc. These inspections can effectively control the quality of the oral liquid.

[0030] The myristicin described in the present application has a CAS number of 607-91-0, which can be used interchangeably with myristicin, Myristicin, Myr and other chemical names thereof to represent the same meaning. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 is the chromatogram of the prepared myristic ether sample;

[0032] Figure 2 The results of the effects of myristicin on the cardiac function of MIRI rats detected by cardiac ultrasound;

[0033] Figure 3 The effect of myristicin on reducing myocardial infarction area in MIRI rats (TTC staining);

[0034] Figure 4 H&E staining was used to observe the effect of myristicin on the histological changes of the heart in MIRI rats (HE staining, magnification 800 times);

[0035] Figure 5 The effects of myristicin on the activities of LDH (Part A), AST (Part B), CK (Part C) and CKMB (Part D) in the serum of MIRI rats;

[0036] Figure 6 The protective effect of myristic ether on H9c2 cells injured by H / R: cytotoxicity (Part A, CCK-8 method), H / R (Part B, CCK-8 method), LDH (Part C) and SOD (Part D);

[0037] Figure 7 The results show that myristic ether reduces apoptosis of H9c2 cells after H / R injury (TUNEL staining, magnification 400 times). DETAILED DESCRIPTION

[0038] Related experimental instruments and materials

[0039]

[0040]

[0041] Embodiment 1 Preparation of myristic ether:

[0042] Take nutmeg medicinal material, crush it, add 8 times the amount of 95% ethanol, soak it overnight, heat and reflux to extract twice, each time for 2 hours; add 6 times the amount of 70% ethanol to the residue, heat and reflux to extract twice, each time for 2 hours. Reduce pressure to recover ethanol until there is no alcohol taste, and obtain an extract. After the extract is redissolved and adsorbed on 1.5 times the amount of diatomaceous earth and completely dried, it is placed in a constant pressure funnel and refluxed with petroleum ether, dichloromethane, ethyl acetate, and methanol in turn, and concentrated under reduced pressure to a thick paste to obtain various parts. The petroleum ether part is gradient eluted with a petroleum ether-ethyl acetate system (100:1~0:1), and the nutmeg ether sample is separated repeatedly by silica gel column chromatography and other methods (see Figure 1 ).

[0043] Purity:>98%

[0044] Instrument: Waters 2695;

[0045] Chromatographic column: Agilent ZORBAX Eclipse Plus C18, 4.6*100mm, 3.5μm

[0046] Mobile phase: methanol-water 57:43;

[0047] Flow rate: 1.0ml / min;

[0048] Column temperature: 25°C;

[0049] Detection wavelength: UV-276nm

[0050] The product chromatogram is as follows Figure 1 shown.

[0051] Example 2 Study on the cardioprotective effect of myristicin on MIRI rats

[0052] Establishment of rat MIRI model:

[0053] Sixty SPF SD rats were randomly divided into 6 groups: Sham group (10 rats), MIRI group (10 rats), MIRI+myristic acid ether (10 ml kg -1 ) group (10), MIRI + myristic acid ether (20 ml kg -1 )(10), MIRI+myristic acid ether (40ml·kg -1)(10), MIRI+DZT(Diltiazem)(20mg·kg -1 )(10 rats). Adaptive feeding for 3-5 days. The low, medium and high dose groups of myristicin and the DZT group were given corresponding drugs (prepared with 3% Tween 80, first add Tween-80, mix and dissolve, then add normal saline), once a day for 7 consecutive days. The Sham group and DCM group were given the same amount of normal saline. The body weight of the rats was recorded every day for one week of administration.

[0054] One week after administration, MIRI modeling was performed, and myocardial ischemia was induced by ligating the left anterior descending branch of the rat coronary artery. Briefly, 60 SD rats were anesthetized by intraperitoneal injection of sodium pentobarbital (40 mg / kg), intubated in the supine position, and dynamic electrocardiogram monitoring was performed. After depilation, the chest was opened, and the left anterior descending branch was ligated with 6-0 suture for 30 minutes (the ST segment of the electrocardiogram was elevated, and the part below the ligation of the heart was observed to be white after ligation, indicating that the ligation position was correct), and then the ligation was opened, and the heart was reperfused for 24 hours. The sham operation group was not ligated. After surgery, when the rats were able to breathe independently, the ventilator was removed. Then they were placed on a constant temperature electric blanket until they could walk, and then put back in the cage. After 24 hours of reperfusion (the first day after modeling), the rats were anesthetized and cardiac ultrasound was performed. On the second day after modeling, blood was drawn from the abdominal aorta, and then the heart was removed and rinsed with saline. Hearts were randomly selected from the experimental group and fixed in 4% paraformaldehyde. Another part (≥5) was stained with TTC, and the remaining hearts were stored at -80°C. Whole blood was collected from the abdominal aorta and centrifuged (3500rpm, 15min), and the supernatant was collected and frozen at -80°C for later use. Morphological and cardiac function examinations:

[0055] After 24 hours of reperfusion, cardiac ultrasound was performed using the Vevo770 ultra-high resolution small animal ultrasound imaging system to evaluate the rat cardiac structure and function. Each parameter was measured 3 times. The operation process was to anesthetize the SD rats with 4% chloral hydrate, depilate the chest, fix the rats in the supine position on the operating table with tape, apply coupling agent to the chest of the SD rats, place the probe at the depilated position (left chest), adjust the probe, and evaluate the echocardiographic parameters in the left parasternal long axis view. Figure 2 .

[0056] To observe the effect of myristicin on myocardial infarction area in rats, TTC staining was performed on myocardial tissue. Figure 3 After all treatments were completed, the heart was removed, rinsed with saline, frozen in liquid nitrogen for 1 min, cut into 5 slices along the cardiac axis, immersed in 2% TTC, incubated at 37°C in the dark for 15 min, and then fixed with 4% paraformaldehyde for 24 h. The heart was photographed with a digital camera, and the proportion of the infarct area was determined based on the images obtained.

[0057] The remaining rat hearts were fixed with 4% formaldehyde. 5 mm tissue sections were stained with hematoxylin and eosin. Morphological examination was performed under an optical microscope. Figure 4 .

[0058] like Figure 2 As shown, M-mode echocardiography was used to measure cardiac parameters to explore the effect of myristicin on the cardiac function of MIRI rats. Compared with the Sham group, the left ventricular ejection fraction (EF) and left ventricular contraction fraction (FS) of the MIRI group rats were significantly decreased, indicating myocardial contractile dysfunction; compared with the MIRI group, the left ventricular ejection fraction (EF) and left ventricular contraction fraction (FS) of the myristicin (10ml / kg, 20ml / kg, 40ml / kg) administration group and the DZT group were significantly increased in the myristicin high, medium, low dose groups and the DZT group, but still lower than the Sham group, indicating that the cardiac contractile function of the rats was protected. This suggests that myristicin can improve the myocardial contractile function of rats after MIRI and has a protective effect on the heart of MIRI rats.

[0059] like Figure 3 As shown, the myocardial infarction area is white and the non-infarction area is red. Observation showed that there was no myocardial infarction in the sham operation group, but there was obvious myocardial infarction in the MIRI group. Compared with the MIRI group, the myocardial infarction area in the myristic ether (10ml / kg, 20ml / kg, 40ml / kg) administration group and the DZT group was significantly reduced, indicating that the myocardial infarction damage in rats was alleviated. This suggests that myristic ether can reduce the myocardial infarction area in MIRI rats and has a protective effect on the heart of MIRI rats.

[0060] like Figure 4 As shown, H&E staining showed that the myocardial fibers of Sham heart tissue were arranged regularly and the myocardial cells were normal in morphology. Compared with the Sham group, the myocardial tissue structure of MIRI group rats was disordered, interstitial edema, irregular nucleus size, enlarged gaps, and inflammatory cell infiltration. Compared with the MIRI group, the myristic ether (10ml / kg, 20ml / kg, 40ml / kg) administration group and the DZT group reduced the myocardial interstitial edema, myocardial cell morphology changes and inflammatory cell infiltration in MIRI rats. This shows that myristic ether has a protective effect on the heart of MIRI rats.

[0061] Plasma collection and biochemical testing:

[0062] Blood samples were collected from the abdominal aorta of rats using a 10 ml syringe under chloral hydrate anesthesia. After the blood was allowed to stand at room temperature for 4 h, it was rotated at 3500 r / min. -Centrifuge at 22℃ for 15min, and store the supernatant at -20℃. The rats were fixed on cardboard and the hearts were stored at -80℃. The activities of CKMB, LDH, CK, and AST in plasma were then measured using an automatic biochemical analyzer AU480 according to the instructions of the commercial test kit purchased by Sinopharm Biotechnology Co., Ltd. The results are shown in Figure 5 .

[0063] like Figure 5 As shown in the data, compared with the Sham group, the MIRI group rats had significantly increased AST, CK, CKMB and LDH levels; compared with the MIRI group, the myristic ether (10ml / kg, 20ml / kg, 40ml / kg) administration group and the DZT group had significantly reduced AST, CK, CKMB and LDH levels, indicating that myristic ether can reduce the enzyme activities of AST, CK, CKMB and LDH and play a cardioprotective role.

[0064] Example 3 Study on the mechanism of the protective effect of myristic ether on H9c2 cardiomyocytes H / R Cell viability was detected by CCK-8 method:

[0065] The protective effect of myristic ether on H9c2 cells induced by H / R (Hypoxia / Reoxygenation, H / R) was detected. In this experiment, a 96-well cell culture plate was used, and a density of 1×10 4 100ul of cell suspension of cells / mL. After 24h of cell plating, the cells reached the logarithmic growth phase. 96-well plate grouping: Control group, Model group (H / R group), H / R+Myr-12.5uM group, H / R+Myr-25uM group, H / R+Myr-50uM group. After 24 hours of pre-administration of the drug-treated group, the model group and the drug-treated group were treated with H / R. The high-glucose DMEM medium in the culture plate was first sucked off, and then ordinary DMEM medium was added, and it was placed in a CO2 anaerobic glove box at 37°C constant temperature incubator for 4h. Then the cell culture plate was taken out of the anaerobic glove box, the sugar-free DMEM medium was sucked off, and fresh high-glucose DMEM medium preheated to 37°C was added, and it was placed in a 37°C carbon dioxide incubator for 12h. During the culture process, the carbon dioxide cell culture incubator was ventilated with air containing 5% CO2 and saturated humidity.

[0066] The H9c2 cardiomyocytes in the control group were placed in a carbon dioxide cell culture incubator with 5% CO2 saturated air and no other treatment was performed. Figure 6 .

[0067] like Figure 6As shown, after 24h treatment with 1.5625uM, 3.125uM, 6.25uM, 12.5uM, 25uM, 50uM, 100uM, and 200uM of myristic acid, there was no significant difference in cell survival rate compared with the Control group. After H / R treatment, the cell survival rate of the Model group was significantly reduced compared with the Control group; compared with the Model group, the myristic acid (12.5uM, 25uM, 50uM) administration group could significantly increase the cell survival rate. The results suggest that myristic acid can alleviate H9c2 cell H / R injury and play a protective role in cardiomyocytes.

[0068] LDH and SOD detection:

[0069] After H / R treatment, the cell culture supernatant was collected and a lactate dehydrogenase assay kit (Cat. No. A020-2, Nanjing Jiancheng Bioengineering Institute) was used according to the instructions. Finally, the absorbance value was measured at a wavelength of 450 nm and quantified.

[0070] Cell samples were collected and the superoxide dismutase (SOD) assay kit (Cat. No. A001-3, Nanjing Jiancheng Bioengineering Institute) was used according to the instructions. Finally, the absorbance value was measured at a wavelength of 450 nm and quantified. The results are shown in Figure 6 .

[0071] like Figure 6 As shown, compared with the Control group, the LDH activity in the cell supernatant of the Model group was significantly increased, and the intracellular SOD activity was significantly decreased, indicating that the cardiomyocytes in the Model group were acutely damaged; compared with the Model group, the myristic ether (12.5uM, 25uM, 50uM)-administered groups could significantly reduce the LDH level in the H9c2 cell supernatant and increase the intracellular SOD enzyme activity. The results suggested that myristic ether could reduce the LDH leakage of H9c2 cells after H / R, enhance the intracellular SOD activity, and play a protective role in cardiomyocytes.

[0072] TUNEL assay to detect cell apoptosis:

[0073] H9c2 cells were cultured in 24-well plates, and the cells were given drugs and treated with hypoxia for 4 hours, followed by reoxygenation for 12 hours. The cells were washed once with PBS, fixed with 4% paraformaldehyde for 30 minutes, washed again with PBS, and PBS containing 0.3% TritonX-100 was added. The cells were incubated at room temperature for 5 minutes. TUNEL detection solution was prepared according to 50ul (5ul TdT enzyme + 45ul fluorescent labeling solution) for one sample. After washing with PBS twice, 50ul TUNEL detection solution was added to the sample, incubated at 37°C in the dark for 60min, washed three times with PBS, and observed under a fluorescence microscope after sealing with anti-fluorescence quenching sealing solution. Three fields of view were selected for each sample, and the process was repeated three times. The results are shown in the table. Figure 7 .

[0074] like Figure 7 As shown, compared with the Control group, the number of TUNEL-positive cells in the Model group was significantly increased; compared with the Model group, the number of TUNEL-positive cells in the myristic ether (12.5uM, 25uM, 50uM) administration groups was significantly decreased. The results suggest that myristic ether can reduce the apoptosis of H9c2 cells after H / R and play a protective role in cardiomyocytes.

Claims

1. Application of myristic ether in the preparation of drugs for treating or preventing cardiovascular diseases.

2. The use according to claim 1, wherein the cardiovascular disease is myocardial ischemia-reperfusion injury.

3. The use according to claim 1 or 2, wherein the drug provides one or more of the following effects: (1) Reduce myocardial infarction area; (2) Improve myocardial contractile function; (3) Reduce myocardial interstitial edema, myocardial cell morphological changes, and inflammatory cell infiltration; (4) Reduce the levels of AST, CK, CKMB, and LDH in the blood; (5) Reduce cardiomyocyte damage and death; (6) Reduce LDH leakage from myocardial cells and enhance intracellular SOD activity; (7) Reduce myocardial cell apoptosis.

4. The use according to claim 1 or 2, wherein myristicin is the only active ingredient in the drug.

5. The use according to claim 1 or 2, wherein the medicine further comprises a pharmaceutically acceptable excipient.

6. The use according to claim 5, wherein the pharmaceutically acceptable excipient is selected from one or more of fillers, binders, lubricants, disintegrants, coating agents, capsule shells, solvents, cosolvents, emulsifiers, pH regulators, osmotic pressure regulators, antioxidants, preservatives, flavoring agents, and colorants.

7. The use according to claim 1 or 2, wherein the drug is in an oral or parenteral dosage form.

8. The use according to claim 7, wherein the medicine is in the form of tablets, capsules, oral liquids, granules, pills, water injections, or powder injections.

9. The use according to claim 8, wherein the medicine is in the form of an oral liquid.

10. The use according to claim 1 or 2, wherein the minimum dosage unit of the drug contains an amount of myristicin equivalent to 10 mg / kg rat.

11. A non-therapeutic method for protecting cardiomyocytes, comprising administering myristic acid ether to cardiomyocytes.

12. The method according to claim 11, which is performed in vitro.

13. The method according to claim 11 or 12, wherein the cardiomyocytes are H9c2 cardiomyocytes.

14. The method according to claim 11 or 12, wherein the cardiomyocytes are treated with 12.5-50 μM myristyl ether. The method according to claim 11 or 12, wherein the cardiomyocytes undergo a hypoxia / reoxygenation process.

Citation Information

Patent Citations

  • Health tea for warming middle energizer and stomach and preparation method thereof

    CN102177994A

  • Composition comprising extract of myristica fragrans or lignan compounds isolated therefrom for treating or preventing vascular diseases

    KR1020130104103A

  • Composition containing myristicin as active ingredient for treating obesity-induced inflammation

    KR1020140086211A

  • Prepaid card system for cross-border payment by local card and management method thereof

    KR1020210150677A